Recordati Rare Company Profile
✉ Email this page to a colleague
What is the competitive landscape for RECORDATI RARE
RECORDATI RARE has twelve approved drugs.
There are ten US patents protecting RECORDATI RARE drugs.
Drugs and US Patents for Recordati Rare
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recordati Rare | ISTURISA | osilodrostat phosphate | TABLET;ORAL | 212801-001 | Mar 6, 2020 | RX | Yes | No | 8,609,862 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Recordati Rare | ISTURISA | osilodrostat phosphate | TABLET;ORAL | 212801-001 | Mar 6, 2020 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Recordati Rare | ISTURISA | osilodrostat phosphate | TABLET;ORAL | 212801-003 | Mar 6, 2020 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Recordati Rare | SIGNIFOR LAR KIT | pasireotide pamoate | FOR SUSPENSION;INTRAMUSCULAR | 203255-002 | Dec 15, 2014 | RX | Yes | No | 9,351,923 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Recordati Rare | ISTURISA | osilodrostat phosphate | TABLET;ORAL | 212801-001 | Mar 6, 2020 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Recordati Rare | COSMEGEN | dactinomycin | INJECTABLE;INJECTION | 050682-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Recordati Rare
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Recordati Rare | NEOPROFEN | ibuprofen lysine | INJECTABLE;INTRAVENOUS | 021903-001 | Apr 13, 2006 | 6,344,479 | ⤷ Start Trial |
| Recordati Rare | SIGNIFOR | pasireotide diaspartate | SOLUTION;SUBCUTANEOUS | 200677-002 | Dec 14, 2012 | 8,299,209 | ⤷ Start Trial |
| Recordati Rare | SIGNIFOR LAR KIT | pasireotide pamoate | FOR SUSPENSION;INTRAMUSCULAR | 203255-001 | Dec 15, 2014 | 6,225,284 | ⤷ Start Trial |
| Recordati Rare | SIGNIFOR | pasireotide diaspartate | SOLUTION;SUBCUTANEOUS | 200677-001 | Dec 14, 2012 | 8,299,209 | ⤷ Start Trial |
| Recordati Rare | SIGNIFOR | pasireotide diaspartate | SOLUTION;SUBCUTANEOUS | 200677-003 | Dec 14, 2012 | 8,299,209 | ⤷ Start Trial |
| Recordati Rare | SIGNIFOR | pasireotide diaspartate | SOLUTION;SUBCUTANEOUS | 200677-001 | Dec 14, 2012 | 6,225,284 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for RECORDATI RARE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Injection | 10 mg/mL, 2 mL vial | ➤ Subscribe | 2010-10-01 |
International Patents for Recordati Rare Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Iceland | 8480 | ⤷ Start Trial |
| Australia | 2006283105 | ⤷ Start Trial |
| Peru | 20090387 | ⤷ Start Trial |
| Japan | 2018150326 | ⤷ Start Trial |
| Japan | 6425688 | ⤷ Start Trial |
| Mexico | 2008002545 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Recordati Rare Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1307486 | 132012902062571 | Italy | ⤷ Start Trial | PRODUCT NAME: PASIREOTIDE DIASPARTATO(SIGNIFOR); AUTHORISATION NUMBER(S) AND DATE(S): EU71/12/753/001-012, 20120424 |
| 2523731 | 122020000026 | Germany | ⤷ Start Trial | PRODUCT NAME: OSILODROSTAT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ DAVON, EINSCHLIESSLICH OSILODROSTATDIHYDROGENPHOSPHAT; REGISTRATION NO/DATE: EU/1/19/1407 20200109 |
| 2523731 | 202040016 | Slovenia | ⤷ Start Trial | PRODUCT NAME: OSILODROSTAT OR ITS PHARMACEUTICALLY ACCEPTABLE SALT INCLUDING OSILODROSTAT DIHYDROGEN PHOSPHATE; NATIONAL AUTHORISATION NUMBER: EU/1/19/1407; DATE OF NATIONAL AUTHORISATION: 20200109; AUTHORITY FOR NATIONAL AUTHORISATION: EU |
| 1686964 | CA 2015 00026 | Denmark | ⤷ Start Trial | PRODUCT NAME: PASIREOTID ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF ELLER ET HVILKET SOM HELST HYDRAT DERAF, HERUNDER PASIREOTIDDIASPARTAT; REG. NO/DATE: EU/1/12/753 20141119 |
| 2523731 | LUC00159 | Luxembourg | ⤷ Start Trial | PRODUCT NAME: OSILODROSTAT OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, Y COMPRIS LE DIHYDROGENOPHOSPHATE D'OSILODROSTAT; AUTHORISATION NUMBER AND DATE: EU/1/19/1407 20200113 |
| 1686964 | 300716 | Netherlands | ⤷ Start Trial | PRODUCT NAME: PASIREOTIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN OF EEN HYDRAAT DAARVAN; REGISTRATION NO/DATE: EU/1/12/753 20141119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.

